Team:Tokyo Tech/Safety

From 2014.igem.org

(Difference between revisions)
 
(25 intermediate revisions not shown)
Line 1: Line 1:
<html xmlns="http://www.w3.org/1999/xhtml">
<html xmlns="http://www.w3.org/1999/xhtml">
-
<meta name="keywords" content="" />
+
<meta name="keywords" content="iGEM,2014,Tokyo_Tech,Bank E.coli" />
-
<meta name="description" content="" />
+
<meta name="description" content="iGEM2014 Wiki pages" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<title>Tokyo_Tech</title>
<title>Tokyo_Tech</title>
<body>
<body>
-
<link rel="stylesheet" href="https://2014.igem.org/Team:Tokyo_Tech/style.css?action=raw&ctype=text/css" type="text/css" media="screen"/>
+
<link rel="stylesheet" href="https://2014.igem.org/Team:Tokyo_Tech/style2.css?action=raw&ctype=text/css" type="text/css" media="screen"/>
<div id="wrapper">
<div id="wrapper">
<div id="header">
<div id="header">
<div id="logo">
<div id="logo">
-
<a href="http://www.titech.ac.jp/"><img src="https://static.igem.org/mediawiki/2014/thumb/b/b7/Tokyo_Tech_Logo.png/613px-Tokyo_Tech_Logo.png" alt="" width="212" height="207" /></a>
+
 
-
</div>
+
<a href="https://2014.igem.org/Main_Page"><img src="https://static.igem.org/mediawiki/2014/thumb/8/84/Tokyo_Tech_iGEM_logo.png/794px-Tokyo_Tech_iGEM_logo.png" width="90" /></a></div>
-
</div>
+
        </div>
<!-- end #header -->
<!-- end #header -->
-
<div id="menu">
+
 +
        <a href="http://www.titech.ac.jp/english/index.html" id="logo-link"></a>
 +
 
 +
        <div id="menu">
<ul>
<ul>
<li><a href="https://2014.igem.org/Team:Tokyo_Tech">Home</a></li>
<li><a href="https://2014.igem.org/Team:Tokyo_Tech">Home</a></li>
-
<li><a href="#">Project</a>
+
<li><a href="https://2014.igem.org/Team:Tokyo_Tech/Project">Project</a></li>
-
<ul>
+
-
<li><a href="#">Bank</a></li>
+
-
        <li><a href="#">Fertilier</a></li>
+
-
  </ul>
+
-
</li>
+
<li><a href="#">Experiment</a>
<li><a href="#">Experiment</a>
-
<ul>
+
  <ul>
-
<li><a href="#">Assay1</a></li>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Experiment/Plux and Prhl reporter assay" style="width:400px; margin-left:-135px;">Plux and Prhl reporter assay</a></li>
-
        <li><a href="#">Assay2</a></li>  
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Experiment/Prhl_reporter_assay" style="width:400px; margin-left:-135px;">Improved Prhl reporter assay</a></li>
-
  </ul>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Experiment/C4HSL-dependent_3OC12HSL_production" style="width:400px; margin-left:-135px;">C4HSL-dependent 3OC12HSL production</a></li>
 +
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Experiment/3OC12HSL-dependent_C4HSL_production" style="width:400px; margin-left:-135px;">3OC12HSL-dependent C4HSL production</a></li>
 +
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Experiment/Symbiosis_confirmation_by_co-culture" style="width:400px; margin-left:-135px;">Mutualism Confirmation ~Co-culture Assay~</a></li>  
 +
  </ul>
</li>
</li>
-
<li><a href="#">Modelling</a>
+
<li><a href="#">Modeling</a>
-
<ul>
+
                          <ul>
-
<li><a href="#">Bank</a></li>
+
                              <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Modeling/Overview"  style="width:400px; margin-left:-135px;">Overview</a></li>
-
        <li><a href="#">Fertilier</a></li>
+
                              <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Modeling/Growth Conditions For Company And Customer"  style="width:400px; margin-left:-135px;">Growth Conditions For Company And Customer</a></li>
-
  </ul>
+
                              <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Modeling/Analysis of C4HSL-dependent Switch" style="width:400px; margin-left:-135px;">Analysis of C4HSL-dependent Switch</a></li>
-
</li>
+
                              <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Modeling/Economic Wave"  style="width:400px; margin-left:-135px;">Economic Wave</a></li>
-
<li><a href="#">Parts</a></li>
+
                          </ul>
-
<li><a href="https://2014.igem.org/Team:Tokyo_Tech/Policy_and_Practices"  
+
                        </li>
-
                        style="padding-top:4px; height:50px;">Policy and Practices</a></li>
+
<li><a href="https://2014.igem.org/Team:Tokyo_Tech/Parts">Parts</a></li>
 +
<li><a href="https://2014.igem.org/Team:Tokyo_Tech/Policy_and_Practices" style="height:50px; padding-top:3px;">Policy and Practices</a></li>
<li class="current_page_item"><a href="#">More</a>
<li class="current_page_item"><a href="#">More</a>
-
<ul>
+
    <ul>
-
<li><a href="https://2014.igem.org/Team:Tokyo_Tech/About_Us">About Us</a></li>
+
<li><a href="https://2014.igem.org/Team:Tokyo_Tech/About_Us" style="width:240px; margin-left:-53px;">About Us</a></li>
-
        <li><a href="#">Safety</a></li>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Safety" style="width:240px; margin-left:-53px;">Safety</a></li>
-
        <li><a href="#">Attribution</a></li>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Attribution_and_Contribution" style="width:240px; margin-left:-53px;">Attribution and Contribution</a></li>
-
        <li><a href="#">Collaboration</a></li>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Collaboration" style="width:240px; margin-left:-53px;">Collaboration</a></li>
-
        <li><a href="#">Judging Form</a></li>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Judging_Form" style="width:240px; margin-left:-53px;">Judging Form</a></li>
-
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Sponsors">Sponsors</a></li>
+
        <li><a href="https://2014.igem.org/Team:Tokyo_Tech/Sponsors" style="width:240px; margin-left:-53px;">Sponsors</a></li>
-
  </ul>
+
        <li><a href="https://igem.org/Team.cgi?id=1529" style="width:240px; margin-left:-53px;">Official Team Page</a></li>
 +
    </ul>
</li>
</li>
</ul>
</ul>
-
  </div>
+
      </div>
<!-- end #menu -->
<!-- end #menu -->
 +
 +
<div id="content-header">
 +
 +
        </div>
 +
 +
<!-- end #content-header -->
 +
<div id="page">
<div id="page">
  <div id="content_normal">
  <div id="content_normal">
             <div class="post">
             <div class="post">
-
      <h2 class="title"><a href="https://2014.igem.org/Team:Tokyo_Tech/Policy_and_Practice">Safety</a></h2>
+
      <h2 class="title">Safety</h2>
-
             <span class="meta">Safety informations for our organisms </span>
+
             <span class="meta">Safety information for our organisms </span>
             <div class="entry-long">
             <div class="entry-long">
 +
              <div id="gototop"><a href="#"><img src="https://static.igem.org/mediawiki/2014/5/55/Tokyo_Tech_Go-to-top-icon.png" height="50" /></a></div>
               <table width="900" border="0">
               <table width="900" border="0">
-
 
+
            <tr>
 +
              <td>&nbsp;</td>
 +
            </tr>
             <tr>
             <tr>
               <td class="title-small"><div align="center">Safety Form </div></td>
               <td class="title-small"><div align="center">Safety Form </div></td>
 +
            </tr>
 +
            <tr>
 +
              <td>&nbsp;</td>
 +
            </tr>
 +
            <tr>
 +
              <td>&nbsp;</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 70: Line 89:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-18"><strong>a.) Have your team members received any safety training yet?</strong></td>
+
               <td class="info-18"><strong>a) Have your team members received any safety training yet?</strong></td>
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Yes,we have already received safety training.</td>
+
               <td class="info">- Yes,we have already received safety training.</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 82: Line 101:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Microbiological experiments (including recombinant DNA) Safety in Recombinant DNA Experiments </td>
+
               <td class="info">- Microbiological experiments (including recombinant DNA) Safety in Recombinant DNA Experiments </td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 88: Line 107:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><strong class="info-18">c) Please give a link to the laboratory safety  training requirements of your institution (college, university,  community lab, etc). Or, if you cannot give a link, briefly describe the  requirements.</strong></td>
+
               <td class="info-18"><strong>c) Please give a link to the laboratory safety  training requirements of your institution (college, university,  community lab, etc). Or, if you cannot give a link, briefly describe the  requirements.</strong></td>
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- SAFETY HANDBOOK wrote by Committee for Practice on management of Safety in Tokyo Institure Microbiological experiments (including recombinant DNA) </td>
+
               <td class="info">- SAFETY HANDBOOK wrote by Committee for Practice on management of Safety in Tokyo Institure Microbiological experiments (including recombinant DNA) </td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 109: Line 128:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Our institute has recombinant DNA committee </td>
+
               <td class="info">- Our institute has recombinant DNA committee </td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 118: Line 137:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- <a href="http://www.rpd.titech.ac.jp//rpdiv/somu/docs/idenshikumikaejikken_anzenkanrikisoku.pdf">http://www.rpd.titech.ac.jp//rpdiv/somu/docs/idenshikumikaejikken_anzenkanrikisoku.pdf</a> </td>
+
               <td class="info">- <a href="http://www.rpd.titech.ac.jp//rpdiv/somu/docs/idenshikumikaejikken_anzenkanrikisoku.pdf">http://www.rpd.titech.ac.jp//rpdiv/somu/docs/idenshikumikaejikken_anzenkanrikisoku.pdf</a> </td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 127: Line 146:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- http://www.lifescience.mext.go.jp/bioethics/anzen.html</td>
+
               <td class="info"><a href="http://www.lifescience.mext.go.jp/bioethics/anzen.html">- http://www.lifescience.mext.go.jp/bioethics/anzen.html</a></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 147: Line 166:
              
              
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 154: Line 173:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 1</h3>
               <td><h3 class="info-18">*Risk Group: 1</h3>
-
                 <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                 <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a></h3>
-
                 <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                 <h3 class="info-18"> *Disease risk to humans:No</h3>
                 <h3 class="info-18">*Part number/name: ppX</h3>
                 <h3 class="info-18">*Part number/name: ppX</h3>
                 <h3 class="info-18">*Natural function of part:  exopolyphosphatase</h3>
                 <h3 class="info-18">*Natural function of part:  exopolyphosphatase</h3>
Line 165: Line 184:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 172: Line 191:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 1</h3>
               <td><h3 class="info-18">*Risk Group: 1</h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                   <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                   <h3 class="info-18"> *Disease risk to humans:No</h3>
                   <h3 class="info-18">*Part number/name: phoU </h3>
                   <h3 class="info-18">*Part number/name: phoU </h3>
                   <h3 class="info-18">*Natural function of part:  regulation of the phosphate regulon</h3>
                   <h3 class="info-18">*Natural function of part:  regulation of the phosphate regulon</h3>
Line 183: Line 202:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 190: Line 209:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 1</h3>
               <td><h3 class="info-18">*Risk Group: 1</h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                 <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                 <h3 class="info-18"> *Disease risk to humans:No</h3>
                 <h3 class="info-18">*Part number/name: ydeD </h3>
                 <h3 class="info-18">*Part number/name: ydeD </h3>
                 <h3 class="info-18">*Natural function of part:  transportation of cystein</h3>
                 <h3 class="info-18">*Natural function of part:  transportation of cystein</h3>
Line 201: Line 220:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 208: Line 227:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 1</h3>
               <td><h3 class="info-18">*Risk Group: 1</h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                 <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                 <h3 class="info-18"> *Disease risk to humans:No</h3>
                 <h3 class="info-18">*Part number/name: yfiK</h3>
                 <h3 class="info-18">*Part number/name: yfiK</h3>
                 <h3 class="info-18">*Natural function of part:  transportation of cystein</h3>
                 <h3 class="info-18">*Natural function of part:  transportation of cystein</h3>
Line 220: Line 239:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 227: Line 246:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 1</h3>
               <td><h3 class="info-18">*Risk Group: 1</h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                 <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                 <h3 class="info-18"> *Disease risk to humans:No</h3>
                 <h3 class="info-18">*Part number/name: rpoS </h3>
                 <h3 class="info-18">*Part number/name: rpoS </h3>
                 <h3 class="info-18">*Natural function of part:  regulation of transcription</h3>
                 <h3 class="info-18">*Natural function of part:  regulation of transcription</h3>
Line 238: Line 257:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 245: Line 264:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 1</h3>
               <td><h3 class="info-18">*Risk Group: 1</h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                 <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                 <h3 class="info-18"> *Disease risk to humans:No</h3>
                 <h3 class="info-18">*Part number/name: crl</h3>
                 <h3 class="info-18">*Part number/name: crl</h3>
                 <h3 class="info-18">*Natural function of part:  regulation of transcription, activagtor of rpoS</h3>
                 <h3 class="info-18">*Natural function of part:  regulation of transcription, activagtor of rpoS</h3>
Line 263: Line 282:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 2 </h3>
               <td><h3 class="info-18">*Risk Group: 2 </h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                   <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                   <h3 class="info-18"> *Disease risk to humans:No</h3>
                   <h3 class="info-18">*Part number/name: obcA </h3>
                   <h3 class="info-18">*Part number/name: obcA </h3>
                   <h3 class="info-18">*Natural function of part:  synthesis of oxalic acid</h3>
                   <h3 class="info-18">*Natural function of part:  synthesis of oxalic acid</h3>
Line 274: Line 293:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td><h1>*Species: E. coli MG1655 </h1></td>
+
               <td><h1>*Species: <i>E. coli</i> MG1655 </h1></td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 281: Line 300:
             <tr>
             <tr>
               <td><h3 class="info-18">*Risk Group: 2 </h3>
               <td><h3 class="info-18">*Risk Group: 2 </h3>
-
                   <h3 class="info-18">*Risk Group Source: NIH Guidelines </h3>
+
                   <h3 class="info-18">*Risk Group Source: <a href="http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines">NIH Guidelines </a> </h3>
-
                   <h3 class="info-18"> <em>*Disease risk to humans:</em>No</h3>
+
                   <h3 class="info-18"> *Disease risk to humans:No</h3>
                   <h3 class="info-18">*Part number/name: obcB</h3>
                   <h3 class="info-18">*Part number/name: obcB</h3>
                   <h3 class="info-18">*Natural function of part:  synthesis of oxalic acid</h3>
                   <h3 class="info-18">*Natural function of part:  synthesis of oxalic acid</h3>
Line 304: Line 323:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Without drinking large amount of sample, there is no risk.Such taking might cause irritation to skin,eyes,and respiratory tract.</td>
+
               <td class="info">- Without drinking large amount of sample, there is no risk.Such taking might cause irritation to skin,eyes,and respiratory tract.</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 313: Line 332:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Wihtout drinking large amount of sample, there is no risk.Such taking might cause irritation to skin,eyes,and respiratory tract.</td>
+
               <td class="info">- Wihtout drinking large amount of sample, there is no risk.Such taking might cause irritation to skin,eyes,and respiratory tract.</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 322: Line 341:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Production of AHL might perturbate communications in wild bacteria.</td>
+
               <td class="info">- Production of AHL might perturbate communications in wild bacteria.</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 331: Line 350:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Use of plant hormone in the opposite direction could disrupt growth of crops.Malicious usage of phage might pertubate intestinal flora.</td>
+
               <td class="info">- Use of plant hormone in the opposite direction could disrupt growth of crops.Malicious usage of phage might pertubate intestinal flora.</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 340: Line 359:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Do not eat,drink,smoke,prepare or store foods in laboratories.<br />
+
               <td class="info">- Do not eat,drink,smoke,prepare or store foods in laboratories.<br />
                      -
                      -
                 Wear a lab-coat(white coat) while you are in a bio-lab.<br />
                 Wear a lab-coat(white coat) while you are in a bio-lab.<br />
Line 348: Line 367:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">&nbsp;</td>
+
               <td class="info">&nbsp;</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 360: Line 379:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- Excess produce of oxalic acid may cause urinary stone.(a)<br />
+
               <td class="info">- Excess produce of oxalic acid may cause urinary stone.(a)<br />
                      -
                      -
                 We can farm any poisonous plants easily. (b)<br />
                 We can farm any poisonous plants easily. (b)<br />
Line 369: Line 388:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">&nbsp;</td>
+
               <td class="info">&nbsp;</td>
             </tr>
             </tr>
             <tr>
             <tr>
Line 375: Line 394:
             </tr>
             </tr>
             <tr>
             <tr>
-
               <td class="info-16">- We have to consider potential risks in Bioremediation.
+
               <td class="info">- We have to consider potential risks in Bioremediation.
               When our project grow, limitation of solid use will be needed.</td>
               When our project grow, limitation of solid use will be needed.</td>
             </tr>
             </tr>
Line 388: Line 407:
<!-- end #page -->
<!-- end #page -->
-
<div id="footer-content">
+
<div id="footer-content"></div>
-
+
-
</div>
+
-
<div id="footer">
+
<div id="footer-over">
<div id="footer-over">
-
<p> &copy; Tokyo Institute of Technology iGEM 2014. Design by <a href="http://templated.co" rel="nofollow">TEMPLATED</a>.</p>
+
<p> &copy; Tokyo Institute of Technology iGEM 2014</p>
</div>
</div>
<!-- end #footer-over -->
<!-- end #footer-over -->
</body>
</body>
</html>
</html>

Latest revision as of 01:22, 18 October 2014

Tokyo_Tech

Safety

Safety information for our organisms
 
Safety Form
 
 
1.) Your Training
 
a) Have your team members received any safety training yet?
- Yes,we have already received safety training.
 
b) Please briefly describe the topics that you learned about (or will learn about) in your safety training.
- Microbiological experiments (including recombinant DNA) Safety in Recombinant DNA Experiments
 
c) Please give a link to the laboratory safety training requirements of your institution (college, university, community lab, etc). Or, if you cannot give a link, briefly describe the requirements.
- SAFETY HANDBOOK wrote by Committee for Practice on management of Safety in Tokyo Institure Microbiological experiments (including recombinant DNA)
 
 
2.) Your Local Rules and Regulations
 
a) Who is responsible for biological safety at your institution? (You might have an Institutional Biosafety Committee, an Office of Environmental Health and Safety, a single Biosafety Officer, or some other arrangement.) Have you discussed your project with them? Describe any concerns they raised, and any changes you made in your project based on your discussion.
- Our institute has recombinant DNA committee
 
b) What are the biosafety guidelines of your institution? Please give a link to these guidelines, or briefly describe them if you cannot give a link.
- http://www.rpd.titech.ac.jp//rpdiv/somu/docs/idenshikumikaejikken_anzenkanrikisoku.pdf
 
c) In your country, what are the regulations that govern biosafety in research laboratories? Please give a link to these regulations, or briefly describe them if you cannot give a link.
- http://www.lifescience.mext.go.jp/bioethics/anzen.html
 
 
3.) The Organism and Parts that You Use
 
 

*Species: E. coli MG1655

 

*Risk Group: 1

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: ppX

*Natural function of part: exopolyphosphatase

*How did you acquire it: made by PCR

*How will you use it?: exopolyphosphatase
 

*Species: E. coli MG1655

 

*Risk Group: 1

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: phoU

*Natural function of part: regulation of the phosphate regulon

*How did you acquire it: made by PCR

*How will you use it?: regulation of the phosphate regulon
 

*Species: E. coli MG1655

 

*Risk Group: 1

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: ydeD

*Natural function of part: transportation of cystein

*How did you acquire it: made by PCR

*How will you use it?: transportation of cystein
 

*Species: E. coli MG1655

 

*Risk Group: 1

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: yfiK

*Natural function of part: transportation of cystein

*How did you acquire it: made by PCR

*How will you use it?: transportation of cystein
 

*Species: E. coli MG1655

 

*Risk Group: 1

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: rpoS

*Natural function of part: regulation of transcription

*How did you acquire it: made by PCR

*How will you use it?: regulation of transcription, growth inhibition
 

*Species: E. coli MG1655

 

*Risk Group: 1

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: crl

*Natural function of part: regulation of transcription, activagtor of rpoS

*How did you acquire it: made by PCR

*How will you use it?: regulation of transcription, activagtor of rpoS
 

*Species: Burkholderia glumae

 

*Risk Group: 2

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: obcA

*Natural function of part: synthesis of oxalic acid

*How did you acquire it: Gene synthesis by IDT

*How will you use it?: synthesis of oxalic acid
 

*Species: E. coli MG1655

 

*Risk Group: 2

*Risk Group Source: NIH Guidelines

*Disease risk to humans:No

*Part number/name: obcB

*Natural function of part: synthesis of oxalic acid

*How did you acquire it: Gene synthesis by IDT

*How will you use it?: synthesis of oxalic acid
 
 
4.) Risks of Your Project Now
 
a) Risks to the safety and health of team members, or other people working in the lab:
- Without drinking large amount of sample, there is no risk.Such taking might cause irritation to skin,eyes,and respiratory tract.
 
b) Risks to the safety and health of the general public (if any biological materials escaped from your lab):
- Wihtout drinking large amount of sample, there is no risk.Such taking might cause irritation to skin,eyes,and respiratory tract.
 
c) Risks to the environment (from waste disposal, or from materials escaping from your lab):
- Production of AHL might perturbate communications in wild bacteria.
 
d) Risks to security through malicious mis-use by individuals, groups, or countries:
- Use of plant hormone in the opposite direction could disrupt growth of crops.Malicious usage of phage might pertubate intestinal flora.
 
e) What measures are you taking to reduce these risks? (For example: safe lab practices, choices of which organisms to use.)
- Do not eat,drink,smoke,prepare or store foods in laboratories.
     - Wear a lab-coat(white coat) while you are in a bio-lab.
     - Keep the lab tidy and clean.
     - Put labels on containers.
     - Practice disinfection,sterilization,and washing hands.
 
5.) Risks of Your Project in the Future
 
a) What new risks might arise from your project's growth? (Consider the categories of risk listed in parts a-d of the previous question: lab workers, the general public, the environment, and malicious mis-uses.) Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?
- Excess produce of oxalic acid may cause urinary stone.(a)
     - We can farm any poisonous plants easily. (b)
     - Too many phosphate may cause contamination of environment.(c)
     - Diabetes patient may have danger if he or she intakes Cystein over 1500mg.(a)
 
b) Does your project currently include any design features to reduce risks? Or, if you did all the future work to make your project grow into a popular product, would you plan to design any new features to minimize risks? (For example: auxotrophic chassis, physical containment, etc.) Such features are not required for an iGEM project, but many teams choose to explore them.
- We have to consider potential risks in Bioremediation. When our project grow, limitation of solid use will be needed.
 

Retrieved from "http://2014.igem.org/Team:Tokyo_Tech/Safety"